ライフサイエンスコーパス: inflammatory myopathy

1 aken in any patient with presumed idiopathic inflammatory myopathy.

2 ntrolled therapeutic trials in patients with inflammatory myopathy.

3 ggests an approach to treating patients with inflammatory myopathy.

4 lled therapeutic trials in all patients with inflammatory myopathy.

5 lin-dependent diabetes mellitus, and chronic inflammatory myopathy.

6 atomyositis are three distinct categories of inflammatory myopathy.

7 n as Jo-1) in the pathogenesis of idiopathic inflammatory myopathy.

8 lammation that is the hallmark of idiopathic inflammatory myopathy.

9 omyositis, the most common form of childhood inflammatory myopathy.

10 les, and their reexpression is a hallmark of inflammatory myopathies.

11 rial CMAS scores of children with idiopathic inflammatory myopathies.

12 o provide an update on the major advances in inflammatory myopathies.

13 r advances in clinical research on pediatric inflammatory myopathies.

14 same treatments that are effective in other inflammatory myopathies.

15 n the currently used designation, idiopathic inflammatory myopathies.

16 scle involvement in patients with idiopathic inflammatory myopathies.

17 th and endurance in children with idiopathic inflammatory myopathies.

18 nd help to clarify the pathogenesis of human inflammatory myopathies.

19 s, is important for the correct diagnosis of inflammatory myopathies.

20 al utility in distinguishing sIBM from other inflammatory myopathies.

21 ritic cells in the cause and pathogenesis of inflammatory myopathies.

22 for the maintenance of autoimmune lesions in inflammatory myopathies.

23 uld potentially play a role in certain human inflammatory myopathies.

24 characterizing, and monitoring treatment for inflammatory myopathies.

25 mechanisms in the pathogenesis of idiopathic inflammatory myopathies.

26 design of clinical trials in the idiopathic inflammatory myopathies.

27 pment of better therapies for the idiopathic inflammatory myopathies.

28 xpression at sites of muscle regeneration in inflammatory myopathies.

29 ons sufficient for an autoimmune response in inflammatory myopathies.

30 was an early and consistent feature of human inflammatory myopathies.

31 ignificance of non-immunological features of inflammatory myopathies.

32 non-immunological factors promote idiopathic inflammatory myopathies.

33 important information in the pathogenesis of inflammatory myopathies.

34 ses and clinical syndromes in the idiopathic inflammatory myopathies.

35 Of 36 patients with other inflammatory myopathies, 1 patient had faint MxA stainin

36 y muscle specimens from 67 patients, 54 with inflammatory myopathies, 14 with dermatomyositis.

37 IEW: To review the treatment advances of the inflammatory myopathies, a heterogeneous group of diseas

38 age leading to regeneration may promote some inflammatory myopathies, although much remains to be lea

39 Similar to inflammatory myopathies, amyloid myopathy presents with

40 ized by muscle wasting and weakness, such as inflammatory myopathies and AIDS wasting.

41 The striking association between the inflammatory myopathies and anti-ARS antibodies implies

42 igate TWEAK-Fn14 expression in IBM and other inflammatory myopathies and explore whether TWEAK modula

43 lex class I expression is highly specific to inflammatory myopathies and may be of diagnostic value.

44 scle of patients with mitochondrial disease, inflammatory myopathies and sarcopenia.

45 isease activity and damage in the idiopathic inflammatory myopathies and speculates on possibly usefu

46 The association between the idiopathic inflammatory myopathies and the development of malignanc

47 topathologic overlap between the features of inflammatory myopathies and those of other muscle disord

48 identified consecutively over 12 years, with inflammatory myopathies and weakness that was most sever

49 is applied to data sets involving diabetes, inflammatory myopathies, and Alzheimer's disease, using

50 expressed autoantigens typically present in inflammatory myopathies, and autoantigen expression incr

51 Autoantibodies may be found in humans with inflammatory myopathies, and these play an important rol

52 ar whether it should be considered a primary inflammatory myopathy, and it generally responds poorly

53 ctromyographic and muscle biopsy findings of inflammatory myopathy, and the typical skin rash of derm

54 his large series of patients with idiopathic inflammatory myopathy, anti-Jo-1 antibody levels correla

55 Inflammatory myopathies are a group of autoimmune diseas

56 The idiopathic inflammatory myopathies are an important and treatable g

57 ents pertaining to disease mechanisms in the inflammatory myopathies are discussed, emphasizing those

58 The idiopathic inflammatory myopathies are diseases that can be difficu

59 h as the clinical features of the idiopathic inflammatory myopathies are not easily differentiated fr

60 In humans, the most common inflammatory myopathies are polymyositis, dermatomyositi

61 The inflammatory myopathies are putative autoimmune disorder

62 o distinguish dermatomyositis from the other inflammatory myopathies, as well as from other myopathie

63 The features of these brachio-cervical inflammatory myopathy (BCIM) syndromes were compared wit

64 ogy (IM-EP), illustrated by brachio-cervical inflammatory myopathy (BCIM); histiocytic inflammatory m

65 eroids are the first line of therapy for the inflammatory myopathies, but because of their side effec

66 itors are being used to treat the idiopathic inflammatory myopathies, but their efficacy has not yet

67 as potential etiologic agents of idiopathic inflammatory myopathy, but their relationship to human m

68 Diseases that may mimic the idiopathic inflammatory myopathies can be differentiated more accur

69 poradic inclusion body myositis (sIBM) is an inflammatory myopathy characterized by both degenerative

70 Inclusion body myositis (IBM) is an inflammatory myopathy characterized immunohistologically

71 kievirus B1 Tucson (CVB1(T)) develop chronic inflammatory myopathy (CIM) consisting of hind limb weak

72 om the muscle of mice afflicted with chronic inflammatory myopathy (CIM) was characterized and compar

73 The inflammatory myopathies, commonly described as idiopathi

74 y (IMNM) is considered one of the idiopathic inflammatory myopathies, comprising dermatomyositis, pol

75 enesis and course of the juvenile idiopathic inflammatory myopathies continued this year.

76 m of injury and death of muscle cells in the inflammatory myopathies (dermatomyositis, polymyositis,

77 The major syndromes of chronic inflammatory myopathy (dermatomyositis and polymyositis)

78 Women in whom inflammatory myopathy develops after they receive silico

79 sts, different from mesoangioblasts in other inflammatory myopathies, display a myogenic differentiat

80 All inflammatory myopathies displayed overexpression of dege

81 itis, polymyositis, and the other idiopathic inflammatory myopathies focus primarily on features of m

82 identification of new cells and pathways in inflammatory myopathies has led to deeper mechanistic un

83 development of therapies for the idiopathic inflammatory myopathies have been enabled by recent prog

84 w classification criteria for the idiopathic inflammatory myopathies have been proposed in an effort

85 possible infectious causes of the idiopathic inflammatory myopathies have focused on retroviruses, in

86 anding of the pathogenesis of the idiopathic inflammatory myopathies have served to identify potentia

87 xamine if the muscle fibers in patients with inflammatory myopathies have the potential to behave as

88 and assessment tools to measure function in inflammatory myopathy have just recently emerged this de

89 ty complex upregulation, although typical of inflammatory myopathies, have been shown to occur in som

90 ) is the most common disabling, adult-onset, inflammatory myopathy histologically characterized by in

91 he requirements for an accurate diagnosis of inflammatory myopathy (i.e., polymyositis and dermatomyo

92 The idiopathic inflammatory myopathies (IIM) continue to provide a chal

93 or other autoimmune diseases, the idiopathic inflammatory myopathies (IIM) develop as a result of spe

94 with systemic sclerosis (SSc) and idiopathic inflammatory myopathies (IIM), and HLA-DQA1*0501 is a ri

95 , have not been developed for the idiopathic inflammatory myopathies (IIM), thus limiting our capacit

96 ignificant clinical challenges in idiopathic inflammatory myopathies (IIM).

97 Inflammatory myopathy (IIM) classification criteria have

98 clinical trials of patients with idiopathic inflammatory myopathy (IIM) has varied to date and over

99 The sequelae associated with idiopathic inflammatory myopathy (IIM) often result in disability a

100 ader on immunogenetic advances in idiopathic inflammatory myopathy (IIM) over the past 18 months.

101 American Caucasian patients with idiopathic inflammatory myopathy (IIM).

102 is but without silicone implants (idiopathic inflammatory myopathy; IIM patients).

103 Acquired immune and inflammatory myopathies (IIMs) are typically subdivided

104 we have shown that patients with idiopathic inflammatory myopathies (IIMs) develop autoimmunity to F

105 driving the autoimmune process in idiopathic inflammatory myopathies (IIMs) have not been unraveled,

106 understanding the genetics of the idiopathic inflammatory myopathies (IIMs) in the past 2 years, with

107 easing evidence suggests that the idiopathic inflammatory myopathies (IIMs) result from certain envir

108 This update on childhood idiopathic inflammatory myopathies (IIMs) reviews recent progress i

109 e to the etiology of the juvenile idiopathic inflammatory myopathies (IIMs), which are systemic autoi

110 on and classification of acquired immune and inflammatory myopathies (IIMs).

111 dates in groups of patients with idiopathic inflammatory myopathies (IIMs).

112 Muscular dystrophies (MDs) and inflammatory myopathies (IMs) are debilitating skeletal

113 yositis is the most common of the idiopathic inflammatory myopathies in children.

114 l blood mononuclear cells from patients with inflammatory myopathies, in order to provide insight int

115 Evaluation of new therapies for the inflammatory myopathies is complicated by the heterogene

116 g inclusion body myositis from the other two inflammatory myopathies is the lack of responsiveness to

117 ng humoral characteristics of the idiopathic inflammatory myopathies is the specific targeting of com

118 The muscle microenvironment in inflammatory myopathy is complex.

119 atomyositis (JDM), the most common pediatric inflammatory myopathy, is a systemic vasculopathy affect

120 our understanding of the juvenile idiopathic inflammatory myopathies (JIIMs).

121 pha (TNF-alpha), a monokine overexpressed in inflammatory myopathies, led to a marked up-regulation o

122 al inflammatory myopathy (BCIM); histiocytic inflammatory myopathies, like sarcoid myopathy; and infl

123 Spontaneously occurring canine inflammatory myopathies may be good parallel disorders a

124 rstanding the role of mMyBP-C in this canine inflammatory myopathy may advance our knowledge of mecha

125 n the ability to diagnose several idiopathic inflammatory myopathy mimics.

126 of myopathy, including muscular dystrophies, inflammatory myopathies, mitochondrial/metabolic myopath

127 ealed none of these characteristics found in inflammatory myopathy muscle tissue.

128 In dogs with inflammatory myopathy, muscle-specific autoantibodies ha

129 In contrast to other inflammatory myopathies, myositis-specific autoantibodie

130 phisticated agents for myasthenia gravis and inflammatory myopathies, neuroprotection with vitamin E

131 Juvenile dermatomyositis (DM) is a chronic inflammatory myopathy of childhood primarily affecting t

132 inclusion body myositis (s-IBM) is a chronic inflammatory myopathy of unknown pathogenesis.

133 ercise intervention studies or in studies of inflammatory myopathies or muscle fibrosis, permitting g

134 The idiopathic inflammatory myopathies or myositis syndromes (the most

135 n their rarity and diversity, the idiopathic inflammatory myopathies, or myositis syndromes, have ben

136 pus erythematosus, Wegener's granulomatosis, inflammatory myopathy, or polyarteritis nodosa rather th

137 dermatomyositis and the juvenile idiopathic inflammatory myopathies over the past year included the

138 new findings implicate non-immune factors in inflammatory myopathy pathogenesis.

139 forefront in evaluating difficult idiopathic inflammatory myopathy patients.

140 In the human inflammatory myopathies (polymyositis and dermatomyositi

141 X activity in muscle fibres of patients with inflammatory myopathies provides useful prognostic infor

142 ology and much about the pathogenesis of the inflammatory myopathies remain a mystery.

143 The etiology and pathogenesis of human inflammatory myopathies remain unclear.

144 these molecules and the pathogenesis of the inflammatory myopathies remains obscure.

145 Canine inflammatory myopathies share clinical and histological

146 had muscle biopsy findings "consistent with inflammatory myopathy." She was referred to Johns Hopkin

147 the pathogenesis of muscular dystrophies and inflammatory myopathies shows complex interactions betwe

148 In patients with juvenile idiopathic inflammatory myopathy, stair-stepping exercise induces s

149 e distinguished from the commoner idiopathic inflammatory myopathies such as polymyositis and dermato

150 ment of chemokines in muscular dystrophy and inflammatory myopathies suggest that targeting specific

151 Our understanding of the pathogenesis of the inflammatory myopathies suggests an interplay between ad

152 Recent literature in inflammatory myopathies suggests that both immune (cell-

153 ids remain the mainstay of treatment for the inflammatory myopathies, their use is complicated by man

154 pected gene transcripts using microarrays in inflammatory myopathy tissue has led to the discovery of

155 In the case of inflammatory myopathies, we have correctly identified th

156 ce of gene expression in the pathogenesis of inflammatory myopathies, we performed microarray experim

157 nts of therapeutic strategies for idiopathic inflammatory myopathies were recently published.

158 nt discoveries about the pathogenesis of the inflammatory myopathies, which are not currently of prac

159 rmed in 19 patients with juvenile idiopathic inflammatory myopathy who performed stair-stepping exerc

160 or assessing target organs of the idiopathic inflammatory myopathies will likely evolve as more sensi

161 e the major epidemiological evidence linking inflammatory myopathies with cancer, and will use this e

162 Dermatomyositis is one of the idiopathic inflammatory myopathies with characteristic cutaneous ma

163 omyositis with vascular pathology from other inflammatory myopathies with skin changes that have prom

164 atory myopathies, like sarcoid myopathy; and inflammatory myopathies with vacuoles, aggregates and mi

165 Inclusion body myositis (IBM) is an inflammatory myopathy with distinctive clinicopathologic

166 oradic inclusion body myositis, a late-onset inflammatory myopathy with prominent mitochondrial chang

167 Inflammatory myopathy, with muscle fiber invasion by leu